JULÄINE™ is offered as a collagen stimulator containing poly-L-lactic acid. New studies report changes after the first or second session. These results may sound clear, but they do not yet answer the essential questions: what was actually measured, how was the study designed and can improved safety be inferred from it? A responsible assessment therefore begins not with a promise, but with study design, mechanism and the individual treatment goal.
Poly-L-lactic acid is commonly abbreviated to PLLA. After injection, the material itself is not the only focus. The intended change is expected to develop through a controlled tissue response and the formation of new collagen structures. This process is gradual and remains biologically individual. It also means that a brand name alone cannot predict the degree of change or whether the procedure is suitable for a particular face or concern.
What is JULÄINE™ and how does poly-L-lactic acid work?
JULÄINE™ is an injectable PLLA product. The scientific product study describes the material as PLLA-LASYNPRO™. The injected particles trigger a local response involving connective-tissue cells, among others. New collagen may subsequently form. The material and the body’s response therefore interact over time. For this reason, the treatment is not accurately explained as simply filling a depression.
The term collagen stimulator should nevertheless not be interpreted as a guarantee of firmer, younger or permanently altered skin. Collagen is only one component of tissue. Baseline anatomy, treatment area, injection plane, amount, technique and individual response all influence the result. Even a change measured in a study cannot automatically be transferred to every person. In consultation, the specific feature that is meant to change is therefore more important than a general hope of regeneration.
How does PLLA differ from a hyaluronic acid filler?
Hyaluronic acid fillers are often selected when shape, contour or volume is intended to change immediately. Depending on the product, they can bind water and mechanically support tissue. PLLA follows a different primary principle, with the gradual tissue response playing a more prominent role. The categories are not completely separate, however, because fillers can also trigger biological responses and a collagen stimulator can influence visible volume. The specific product therefore matters more than its marketing category.
This difference does not create a ranking. A procedure is not automatically more natural, modern or superior simply because its effect appears later. Someone seeking a clearly defined change in contour is asking a different question from someone considering a gradual change in tissue structure. Sometimes neither procedure is appropriate. A sound medical assessment separates skin quality, volume, movement and proportion before a product is selected or an injection is discouraged.
What do studies show after the first and second session?
A 2026 observational study followed 95 adults across several Italian clinics. After the first session, 59.6 per cent were rated as improved by physicians. After the second session, 74.4 per cent were rated as improved and 20 per cent as much improved. This suggests a possible gradual change, not a guaranteed rapid result. The study had no control group, and only 56 participants returned questionnaires at the final assessment.
A second prospective multicentre study examined 36 women over six months. Its protocol allowed up to three administrations at baseline and after four and eight weeks. It reported improvements on standardised wrinkle and volume scales, imaging changes and mainly temporary local reactions. This study was also non-randomised and had no control group. The publication itself calls for larger randomised trials. Both studies provide clinical signals, but neither a personal outcome guarantee nor a direct comparison with other products.
Which expectations are realistic?
A realistic expectation is that any possible change will be assessed gradually. A guaranteed lifting effect, an exactly predictable amount of collagen or a result identical to someone else’s photographs is not realistic. Before-and-after images of other people reflect neither one’s own anatomy nor one’s own tissue response. They may also create expectations that ignore differences in lighting, expression, camera angle and timing. The treatment goal should therefore be described in observable, individual terms.
The phrase natural-looking change also needs a clear meaning. For some people it means retaining their facial features while softening a tired appearance. Others associate it with greater firmness or a softer fold. These goals are not the same. Before PLLA treatment, the main treatment area, the changes that are explicitly not wanted and the way an appropriate result will later be assessed together should therefore be discussed.
Which risks belong in the consent discussion?
Pain, redness, swelling, tenderness or bruising can occur after injections. With collagen stimulators, palpable or visible nodules, inflammatory reactions, infection and unwanted contour changes are also important consent topics. Whether and how often a reaction occurs cannot be predicted with certainty for an individual. A small product study without serious events cannot rule out rare complications.
As with other facial injections, there is a rare but potentially serious risk of a vascular complication. A systematic review identified individual published cases of visual loss following PLLA injections. Case reports do not provide a reliable incidence, but they demonstrate why anatomical knowledge, appropriate technique, early recognition of unusual symptoms and a clear emergency pathway are essential. Sudden visual symptoms or other rapidly worsening problems after an injection require immediate medical assessment.
What belongs in the medical consultation before treatment?
A consultation should assess the face at rest and in motion and describe the concern without relying on product names. Previous injections, operations, current symptoms, medication, allergies and relevant medical conditions belong in a complete history. This may indicate that a different time, another procedure or deciding against treatment is more appropriate. A decision should only be made once the goal, material, treatment area, possible alternatives, typical reactions and rare serious risks have been explained clearly.
- Which specific feature is intended to change and which explicitly is not?
- Why is PLLA more appropriate for this goal than another procedure or no injection?
- Which common and rare risks apply to the material, area and technique?
- Which symptoms require immediate medical contact after treatment?
- How will the treatment be documented and the need for any further treatment assessed?
How many sessions, what duration and what cost?
The number and spacing of JULÄINE™ sessions cannot responsibly be stated as a universal schedule. Treatment area, baseline anatomy, amount used, response and desired goal can alter the plan. The same applies to duration. Studies observe groups under defined conditions; they do not create a personal time guarantee. Advertising a fixed number of months or a standard package reduces a medical decision to a figure that means little without an examination.
A flat price would likewise be misleading without a defined scope. Before deciding, it should be clear which medical service, product, amount, documentation and follow-up are planned. PRECIOUS is a private practice for internal medicine, longevity and aesthetic medicine in Wiesbaden. During a personal appointment, a medical assessment can clarify whether PLLA treatment is generally appropriate for the individual situation and which points must be clarified before any possible plan is made.
How can a sound decision about JULÄINE™ be made?
A sound decision combines a limited goal with realistic evidence and complete consent. JULÄINE™ is not a synonym for general skin rejuvenation, and PLLA is not automatically the right answer to every line or volume concern. The procedure is only appropriate if the expected mechanism suits the baseline situation and uncertainty can be acknowledged openly. After an understandable consultation, deciding against treatment or choosing a later time must remain valid options.
Sources
- Cassuto et al.: Post-market observational study of PLLA-LASYNPRO™ in 95 adults, PubMed PMID 42153037.
- Urdiales-Gálvez et al.: Prospective multicentre study of PLLA-LASYNPRO™ in facial treatment, PubMed PMID 41715284.
- Ferreira et al.: Systematic review of the efficacy, durability and safety of facial PLLA and CaHA, PubMed PMID 41184662.
- Young et al.: Systematic review of visual loss following biostimulator injections, PubMed PMID 41263987.